GlassScriptPhysician profile
Jennifer Sheldon
NPI 1548692700
$17,123.62
in general payments reported to CMS, 2019-2025
46 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,531 · 2022: $2,142 · 2023: $1,948 · 2024: $2,260 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,450.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $7,604.56 | 2021-2025 | |
| Novo Nordisk INC | $1,558.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,257.20 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $570.27 | 2021-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $545.80 | 2021-2025 | |
| Amgen INC. | $414.83 | 2021-2025 | Tepezza, Repatha, Evenity |
| Insulet Corporation | $404.76 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $387.02 | 2021-2025 | Korlym |
| Abbott Laboratories | $308.77 | 2021-2025 | Freestyle Libre |
| Tandem Diabetes Care, INC. | $281.50 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $278.15 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $267.37 | 2021-2024 | Unithroid |
| Dexcom, INC. | $263.24 | 2021-2025 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $236.51 | 2021-2022 | |
| Antares Pharma, INC. | $222.39 | 2021-2025 | Xyosted |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $211.28 | 2021-2022 | |
| Abbvie INC. | $193.44 | 2021-2025 | |
| Horizon Therapeutics Plc | $187.30 | 2022-2023 | Tepezza |
| Cequr Corporation | $176.31 | 2022-2025 | Cequr Simplicity |
| Radius Health, INC. | $169.57 | 2021-2025 | Tymlos |
| Mannkind Corporation | $157.47 | 2022-2024 | Afrezza |
| Medtronic, INC. | $156.36 | 2023 | Minimed 780g, Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.66 | 2021-2025 | Jardiance, Trijardy Xr, Synjardy |
| Alexion Pharmaceuticals, INC. | $129.45 | 2021-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $93.93 | 2023-2025 | Yorvipath |
| Kyowa Kirin, INC. | $92.07 | 2024-2025 | Crysvita |
| Embecta Corp. | $90.50 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.40 | 2021-2023 | Cycloset |
| Tolmar, INC. | $72.32 | 2024-2025 | Jatenzo |
| Ascensia Diabetes Care US INC. | $60.31 | 2023 | |
| Verity Pharmaceuticals INC. | $55.70 | 2024-2025 | Tlando |
| Esperion Therapeutics, INC. | $53.72 | 2021 | |
| Clarus Therapeutics INC. | $48.38 | 2021 | |
| Boston Scientific Corporation | $43.91 | 2024-2025 | Watchman Flx |
| Halozyme INC | $42.23 | 2023 | |
| Madrigal Pharmaceuticals | $36.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Amarin Pharma, INC. | $35.48 | 2021 | |
| Bigfoot Biomedical INC | $30.75 | 2022 | |
| Chiesi USA, INC. | $22.77 | 2025 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $22.36 | 2025 | |
| Glaxosmithkline, LLC. | $20.54 | 2025 | Shingrix, Arexvy |
| Redhill Biopharma INC. | $19.89 | 2024 | Talicia |
| Sequel Med Tech, LLC | $18.10 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $16.34 | 2024 | Spravato |
| Pfizer INC. | $15.67 | 2024 | |
| Ibsa Pharma INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Sheldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.